Deals channel feed – Endpoints News

Deals channel feed

European Commission clears AstraZeneca's $39B bid for Alexion and a future in rare diseases. Now there's just a final hurdle

4 years ago

The CRO madness continues as Goldman Sachs-backed buyer group shells out $8.5B for Parexel

4 years ago

Hal Barron's chase for genetic clues leads GlaxoSmithKline back to neuro — and makes new biotech partner $700M richer overnight

4 years ago

The class of molecules behind one of biotech's biggest Alzheimer's failures gets a new lease on life

4 years ago

Merck extends deal to see what else NGM's discovery engine can come up with

4 years ago

Nestlé is betting $525M on a bid to pioneer world's first microbiome drug

4 years ago

Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

4 years ago

Apellis, Beam team up to test base editing against the broad field of complement disorders

4 years ago

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

4 years ago

Gilead, Foresite take an unknown pandemic antiviral public in $250M SPAC deal

4 years ago

Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot

4 years ago

Alzheimer's gold rush inspires $565M deal between Chinese pharma powerhouse and little German biotech

4 years ago

On heels of Aduhelm approval, Bristol Myers jumps back into Alzheimer's race

4 years ago

Roche severs ties with 4D Molecular Therapeutics over blindness gene therapy, marking another setback for the field

4 years ago

EQRx and Exscientia, a pair of self-styled disruptors, team up to overturn the drug pricing apple cart

4 years ago

With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline

4 years ago

Blackstone throws $250M behind Intellia-Cellex quest to combine CRISPR and controllable CAR-Ts

4 years ago

Alfasigma snares EU rights to blood clotting antibody on the hunt for patients taking AstraZeneca's Brilinta

4 years ago

They went from daily to once every two months. But how much longer acting can HIV meds be? ViiV enlists Halozyme's tech to find out

4 years ago

The digital health field continues to boom as SoftBank-backed startup hits unicorn status in SPAC reverse merger

4 years ago

Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med

4 years ago

Bristol Myers breaks the bank on Eisai's folate receptor ADC drug, laying out more than $3B+ for rights

4 years ago

In an effort to safely deliver mRNA, Stanford University teams up with German biotech Evonik

4 years ago

As it awaits pivotal review of lead drug, FibroGen bolsters its early pipeline with licensing deal for galectin program

4 years ago

First page Previous page 73 74 757677 78 79 Next page Last page